Diversified Trust Co Increases Position in Phreesia, Inc. (NYSE:PHR)

Diversified Trust Co raised its position in Phreesia, Inc. (NYSE:PHR - Free Report) by 83.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,616 shares of the company's stock after purchasing an additional 20,260 shares during the period. Diversified Trust Co owned 0.08% of Phreesia worth $1,140,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in PHR. Johnson Financial Group Inc. lifted its holdings in shares of Phreesia by 381.3% in the 4th quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company's stock valued at $28,000 after purchasing an additional 896 shares during the last quarter. Quarry LP raised its holdings in shares of Phreesia by 210.9% in the fourth quarter. Quarry LP now owns 2,835 shares of the company's stock valued at $71,000 after buying an additional 1,923 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Phreesia by 154.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 3,442 shares of the company's stock worth $89,000 after buying an additional 2,090 shares during the period. NewEdge Advisors LLC boosted its stake in shares of Phreesia by 12.1% during the fourth quarter. NewEdge Advisors LLC now owns 4,256 shares of the company's stock worth $107,000 after buying an additional 459 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Phreesia by 1,023.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,660 shares of the company's stock worth $142,000 after buying an additional 5,156 shares during the last quarter. Institutional investors and hedge funds own 92.10% of the company's stock.

Phreesia Price Performance

Shares of NYSE PHR traded up $0.35 during midday trading on Wednesday, hitting $28.84. The company had a trading volume of 248,567 shares, compared to its average volume of 453,883. The firm has a market capitalization of $1.72 billion, a price-to-earnings ratio of -38.91 and a beta of 0.72. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $30.53. The business has a 50-day simple moving average of $25.75 and a two-hundred day simple moving average of $26.16. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.02.

Phreesia (NYSE:PHR - Get Free Report) last issued its earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. The company had revenue of $115.94 million during the quarter, compared to analysts' expectations of $115.00 million. Phreesia had a negative net margin of 9.83% and a negative return on equity of 16.23%. The firm's quarterly revenue was up 14.5% compared to the same quarter last year. During the same period last year, the company posted ($0.05) earnings per share. Equities research analysts anticipate that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. KeyCorp decreased their price objective on Phreesia from $30.00 to $28.00 and set an "overweight" rating for the company in a research report on Wednesday, April 16th. DA Davidson cut their price target on Phreesia from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Wall Street Zen raised Phreesia from a "hold" rating to a "buy" rating in a report on Sunday, June 1st. Needham & Company LLC reissued a "buy" rating and issued a $29.00 price objective on shares of Phreesia in a research note on Thursday, March 13th. Finally, Citigroup restated a "buy" rating on shares of Phreesia in a research note on Wednesday, May 28th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $31.64.

Insider Activity at Phreesia

In other Phreesia news, Director Lisa Egbuonu-Davis sold 2,802 shares of the firm's stock in a transaction dated Thursday, June 26th. The shares were sold at an average price of $27.67, for a total transaction of $77,531.34. Following the completion of the transaction, the director directly owned 22,037 shares in the company, valued at approximately $609,763.79. This trade represents a 11.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michael Weintraub sold 2,569 shares of Phreesia stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $27.86, for a total transaction of $71,572.34. Following the transaction, the director owned 143,039 shares of the company's stock, valued at approximately $3,985,066.54. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 74,334 shares of company stock valued at $1,932,345 in the last 90 days. 5.50% of the stock is owned by corporate insiders.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.